SinoMab BioScience Limited
3681.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.58B
Close$
$-0.00
100.4% downside
Current Fair Value
100.4% downsideOvervalued by 100.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | 0.66 |
| Outstanding Shares | 1,370,997,720 |
Return
| Return on Equity | -90.22% |
|---|---|
| Return on Assets | -47.65% |
| Return on Invested Capital | -57.60% |
Valuation & Multiples
| P/E Ratio | -7.39 |
|---|---|
| PEG | -4.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 292.5 |
| Enterprise Value to EBIT | -5.71 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 22, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SinoMab BioScience Limited
95 employees
CEO: Shui On Leung SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach pre...